Megan Palacio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Megan Palacio has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Clauset
University of Colorado Boulder
1 shared publication - Andrew J. Kavran
University of Colorado Boulder
1 shared publication Annette H. Erbse
Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80309, USA
1 shared publicationGenevieve Roberts
Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80309, USA
1 shared publication- Johannes Rudolph
Department of Biochemistry, University of Colorado Boulder, Boulder, Colorado 80309, United States
1 shared publication Jyothi Mahadevan
Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80309, USA
1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
Threshold and Kinetic Differences between Fifth- and Sixth-Generation High-Sensitivity Cardiac Troponin T in Routine Clinical Care Testing
Background: High-sensitivity cardiac troponin assays, such as troponin T (hs-cTnT), underpin the diagnosis and risk stratification of myocardial injury, with interpretation anchored to the 99th percentile upper reference limit (URL). As clinical laboratories transition from fifth-generation (Gen5) to sixth-generation (Gen6) hs-cTnT assays, analytical shifts may alter threshold crossing and timing of elevation near the 99th percentile URL, where clinical classification is highly consequential. However, real-world data describing the impact of this transition remain limited. Methods: In this retrospective paired analysis, residual specimens from patients undergoing hs-cTnT testing were measured using Roche Gen5/Gen6 assays. A total of 3617 paired measurements from 1847 encounters (1737 patients) were analyzed longitudinally. Patient encounters were assessed for time to elevation above the 99th percentile URL; peak concentration; modeled 0-, 1-, and 3-hour pathway classification; and kinetic behavior. Results: Overall concordance between Gen5 and Gen6 was high for classification of hs-cTnT measurements and encounter peak values relative to the 99th percentile URL. Differences concentrated near the 99th percentile URL, where Gen6 crossed this threshold earlier than Gen5 and the converse was infrequent (2.6% vs 0.1%; P = 0.0001). In the modeled 0/1/3-hour rule-out/rule-in pathway, agreement between assays remained, although some encounters differed in classification between rule-out, indeterminate, and abnormal categories. Gen6 also demonstrated larger relative changes during the rising phase and steeper post-peak declines, with apparent elimination more similar to CK-MB than Gen5. Conclusions: Gen5 and Gen6 hs-cTnT assays demonstrate strong overall agreement, although small analytical differences near decision thresholds produce measurable differences in timing of elevation and modeled clinical classification.
- 20 August 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
Open AccessThreshold and Kinetic Differences between Fifth- and Sixth-Generation High-Sensitivity Cardiac Troponin T in Routine Clinical Care Testing
Background: High-sensitivity cardiac troponin assays, such as troponin T (hs-cTnT), underpin the diagnosis and risk stratification of myocardial injury, with interpretation anchored to the 99th percentile upper reference limit (URL). As clinical laboratories transition from fifth-generation (Gen5) to sixth-generation (Gen6) hs-cTnT assays, analytical shifts may alter threshold crossing and timing of elevation near the 99th percentile URL, where clinical classification is highly consequential. However, real-world data describing the impact of this transition remain limited. Methods: In this retrospective paired analysis, residual specimens from patients undergoing hs-cTnT testing were measured using Roche Gen5/Gen6 assays. A total of 3617 paired measurements from 1847 encounters (1737 patients) were analyzed longitudinally. Patient encounters were assessed for time to elevation above the 99th percentile URL; peak concentration; modeled 0-, 1-, and 3-hour pathway classification; and kinetic behavior. Results: Overall concordance between Gen5 and Gen6 was high for classification of hs-cTnT measurements and encounter peak values relative to the 99th percentile URL. Differences concentrated near the 99th percentile URL, where Gen6 crossed this threshold earlier than Gen5 and the converse was infrequent (2.6% vs 0.1%; P = 0.0001). In the modeled 0/1/3-hour rule-out/rule-in pathway, agreement between assays remained, although some encounters differed in classification between rule-out, indeterminate, and abnormal categories. Gen6 also demonstrated larger relative changes during the rising phase and steeper post-peak declines, with apparent elimination more similar to CK-MB than Gen5. Conclusions: Gen5 and Gen6 hs-cTnT assays demonstrate strong overall agreement, although small analytical differences near decision thresholds produce measurable differences in timing of elevation and modeled clinical classification.
- 1 December 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 4994-5006.e5
The BRCT domain of PARP1 binds intact DNA and mediates intrastrand transfer
- 1 December 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 4994-5006.e5
The BRCT domain of PARP1 binds intact DNA and mediates intrastrand transfer
- Open Access
Optimizing polymerase chain reaction (PCR) using machine learning
Despite substantial standardization, polymerase chain reaction (PCR) experiments frequently fail. Troubleshooting failed PCRs can be costly in both time and money. Using a crowdsourced data set spanning 290 real PCRs from six active research laboratories, we investigate the degree to which PCR success rates can be improved by machine learning. While human designed PCRs succeed at a rate of 55–63%, we find that a machine learning model can accurately predict reaction outcome 81% of the time. We validate this level of improvement by then using the model to guide the design and predict the outcome of 39 new PCR experiments. In addition to improving outcomes, the model identifies 15 features of PCRs that researchers did not optimize well compared to the learned model. These results suggest that PCR success rates can easily be improved by 17–26%, potentially saving millions of dollars and thousands of hours of researcher time each year across the scientific community. Other common laboratory methods may benefit from similar data-driven optimization effort.
Open AccessOptimizing polymerase chain reaction (PCR) using machine learning
Despite substantial standardization, polymerase chain reaction (PCR) experiments frequently fail. Troubleshooting failed PCRs can be costly in both time and money. Using a crowdsourced data set spanning 290 real PCRs from six active research laboratories, we investigate the degree to which PCR success rates can be improved by machine learning. While human designed PCRs succeed at a rate of 55–63%, we find that a machine learning model can accurately predict reaction outcome 81% of the time. We validate this level of improvement by then using the model to guide the design and predict the outcome of 39 new PCR experiments. In addition to improving outcomes, the model identifies 15 features of PCRs that researchers did not optimize well compared to the learned model. These results suggest that PCR success rates can easily be improved by 17–26%, potentially saving millions of dollars and thousands of hours of researcher time each year across the scientific community. Other common laboratory methods may benefit from similar data-driven optimization effort.